Evidence map›Paper›PMID 38247864›Full record

ArticleCells2024

Coronavirus Receptor Expression Profiles in Human Mast Cells, Basophils, and Eosinophils.

Lina Degenfeld-Schonburg, Irina Sadovnik, Dubravka Smiljkovic, Barbara Peter, Gabriele Stefanzl, Clemens Gstoettner, Peter Jaksch, Konrad Hoetzenecker, Clemens Aigner, Christine Radtke and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Immune Response Dynamics and Biomarkers in COVID-19 Patients.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Lina Degenfeld-SchonburgDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Irina SadovnikDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Dubravka SmiljkovicDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Barbara PeterLudwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Gabriele StefanzlDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Clemens GstoettnerDepartment of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-0092-568X
Peter JakschDepartment of Thoracic Surgery, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-4635-3242
Konrad HoetzeneckerDepartment of Thoracic Surgery, Medical University of Vienna, 1090 Vienna, Austria.
Clemens AignerDepartment of Thoracic Surgery, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-7787-991X
Christine RadtkeDepartment of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Vienna, 1090 Vienna, Austria.
Michel ArockLaboratory of Hematology, Pitié-Salpêtrière Hospital, 75651 Paris, France.ORCID 0000-0002-3990-4408
Wolfgang R SperrDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Peter ValentDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-0456-5095
Medical University of Vienna · ATSorbonne Université · FR

Funding

FWF Austrian Science Fund grant P32470-BMedical Scientific Fund of the Mayor of the City of Vienna project number 22016
6 · The paper itself

Abstract

A major problem in SARS-CoV-2-infected patients is the massive tissue inflammation in certain target organs, including the lungs. Mast cells (MC), basophils (BA), and eosinophils (EO) are key effector cells in inflammatory processes. These cells have recently been implicated in the pathogenesis of SARS-CoV-2 infections. We explored coronavirus receptor (CoV-R) expression profiles in primary human MC, BA, and EO, and in related cell lines (HMC-1, ROSA, MCPV-1, KU812, and EOL-1). As determined using flow cytometry, primary MC, BA, and EO, and their corresponding cell lines, displayed the CoV-R CD13 and CD147. Primary skin MC and BA, as well as EOL-1 cells, also displayed CD26, whereas primary EO and the MC and BA cell lines failed to express CD26. As assessed using qPCR, most cell lines expressed transcripts for CD13, CD147, and ABL2, whereas ACE2 mRNA was not detectable, and CD26 mRNA was only identified in EOL-1 cells. We also screened for drug effects on CoV-R expression. However, dexamethasone, vitamin D, and hydroxychloroquine did not exert substantial effects on the expression of CD13, CD26, or CD147 in the cells. Together, MC, BA, and EO express distinct CoV-R profiles. Whether these receptors mediate virus-cell interactions and thereby virus-induced inflammation remains unknown at present.

Indexed as

Dipeptidyl Peptidase 4Mast CellsBasophilsEosinophilsHumansInflammationReceptors, CoronavirusDipeptidyl Peptidase 4Receptors, Coronavirusbasophilseosinophilsinflammationmast cellsSARS-CoV-2 receptors

Identifiers

PMID38247864
PMCPMC10814915
OpenAlexW4390948724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.